Accessibility Menu
 
Hikma Pharmaceuticals Plc logo

Hikma Pharmaceuticals Plc

(OTC) HKMPY

Current Price$37.21
Market Cap$4.00B
Since IPO (2011)+104%
5 Year-36%
1 Year-27%
1 Month+6%

Hikma Pharmaceuticals Plc Financials at a Glance

Market Cap

$4.00B

Revenue (TTM)

$6.47B

Net Income (TTM)

$759.05M

EPS (TTM)

$3.64

P/E Ratio

10.19

Dividend

$1.68

Beta (Volatility)

0.36 (Low)

Price

$37.21

Volume

72

Open

$37.21

Previous Close

$37.21

Daily Range

$37.21 - $37.21

52-Week Range

$31.80 - $56.94

HKMPY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hikma Pharmaceuticals Plc

Industry

Pharmaceuticals

Employees

9,400

CEO

Riad Mishlawi

Headquarters

London, W1S 2HR, GB

HKMPY Financials

Key Financial Metrics (TTM)

Gross Margin

41%

Operating Margin

17%

Net Income Margin

12%

Return on Equity

16%

Return on Capital

13%

Return on Assets

7%

Earnings Yield

9.81%

Dividend Yield

4.51%

Payout Ratio

45.16%

Stock Overview

Market Cap

$4.00B

Shares Outstanding

107.61M

Volume

72

Avg. Volume

1.16K

Financials (TTM)

Gross Profit

$1.34B

Operating Income

$625.46M

EBITDA

$837.95M

Operating Cash Flow

$359.84M

Capital Expenditure

$197.46M

Free Cash Flow

$162.38M

Cash & ST Invst.

$354.00M

Total Debt

$1.65B

Hikma Pharmaceuticals Plc Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$1.68B

+17.3%

Gross Profit

$667.49M

+7.1%

Gross Margin

39.62%

N/A

Market Cap

$4.00B

N/A

Market Cap/Employee

$421.50K

N/A

Employees

9,500

N/A

Net Income

$163.39M

+179.1%

EBITDA

$407.47M

+90.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$1.29B

-34.6%

Accounts Receivable

$1.08B

+36.8%

Inventory

$1.11B

+24.1%

Long Term Debt

$1.53B

+49.0%

Short Term Debt

$114.00M

-29.2%

Return on Assets

7.10%

N/A

Return on Invested Capital

13.38%

N/A

Free Cash Flow

$101.89M

-58.8%

Operating Cash Flow

$229.56M

-33.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DNPUFSumitomo Pharma Co., Ltd.
$11.43-1.47%
ZLDPFZealand Pharma A/S
$47.37-0.98%
GZPHFGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited
$2.34+0.00%
OPHLFOno Pharmaceutical Co., Ltd.
$14.55+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$13.30+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.07+0.05%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.70+0.01%
SOFISoFi Technologies
$16.43+0.02%

Questions About HKMPY

What is the current price of Hikma Pharmaceuticals Plc?

Hikma Pharmaceuticals Plc is trading at $37.21 per share.

What is the 52-week range for Hikma Pharmaceuticals Plc?

Over the past 52 weeks, Hikma Pharmaceuticals Plc has traded between $31.80 and $56.94.

How much debt does Hikma Pharmaceuticals Plc have?

As of the most recent reporting period, Hikma Pharmaceuticals Plc reported total debt of $1.60B.

How much cash does Hikma Pharmaceuticals Plc have on hand?

Hikma Pharmaceuticals Plc reported $328.00M in cash and cash equivalents in its most recent financial results.

What is Hikma Pharmaceuticals Plc’s dividend yield?

Hikma Pharmaceuticals Plc currently has a dividend yield of 4.51%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.